Azenosertib
Cyclin E1+ Platinum-Resistant Ovarian Cancer (PROC) - Monotherapy
Key Facts
About Zentalis Pharmaceuticals
Zentalis Pharmaceuticals is a clinical-stage oncology company dedicated to improving patient lives through innovative cancer therapies. Its core focus is the development of azenosertib, a highly selective WEE1 inhibitor with broad franchise potential, currently in registration-intent Phase 2 and Phase 3 trials for biomarker-defined ovarian cancer. With operations in San Diego and a leadership team experienced in successful biotech exits, Zentalis is strategically positioned to advance its pipeline in areas of high unmet medical need.
View full company profileAbout Zentalis Pharmaceuticals
Zentalis Pharmaceuticals is a clinical-stage oncology company dedicated to improving patient lives through innovative cancer therapies. Its core focus is the development of azenosertib, a highly selective WEE1 inhibitor with broad franchise potential, currently in registration-intent Phase 2 and Phase 3 trials for biomarker-defined ovarian cancer. With operations in San Diego and a leadership team experienced in successful biotech exits, Zentalis is strategically positioned to advance its pipeline in areas of high unmet medical need.
View full company profileAbout Zentalis Pharmaceuticals
Zentalis Pharmaceuticals is a clinical-stage oncology company dedicated to improving patient lives through innovative cancer therapies. Its core focus is the development of azenosertib, a highly selective WEE1 inhibitor with broad franchise potential, currently in registration-intent Phase 2 and Phase 3 trials for biomarker-defined ovarian cancer. With operations in San Diego and a leadership team experienced in successful biotech exits, Zentalis is strategically positioned to advance its pipeline in areas of high unmet medical need.
View full company profileAbout Zentalis Pharmaceuticals
Zentalis Pharmaceuticals is a clinical-stage oncology company dedicated to improving patient lives through innovative cancer therapies. Its core focus is the development of azenosertib, a highly selective WEE1 inhibitor with broad franchise potential, currently in registration-intent Phase 2 and Phase 3 trials for biomarker-defined ovarian cancer. With operations in San Diego and a leadership team experienced in successful biotech exits, Zentalis is strategically positioned to advance its pipeline in areas of high unmet medical need.
View full company profileAbout Zentalis Pharmaceuticals
Zentalis Pharmaceuticals is a clinical-stage oncology company dedicated to improving patient lives through innovative cancer therapies. Its core focus is the development of azenosertib, a highly selective WEE1 inhibitor with broad franchise potential, currently in registration-intent Phase 2 and Phase 3 trials for biomarker-defined ovarian cancer. With operations in San Diego and a leadership team experienced in successful biotech exits, Zentalis is strategically positioned to advance its pipeline in areas of high unmet medical need.
View full company profile